Precision Medicine Quarterly
PMLS
PMLS
Novartis
Novartis

Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women

2021-09-30T11:52:55-05:00September 30th, 2021|

Eli Lilly and Company (NYSE: LLY) and Susan G. Komen®, the world's leading breast cancer organization, launched a new multiyear program to address breast cancer health disparities experienced by Black women in the U.S. Through the partnership, Lilly and Komen will expand existing resources that provide direct support to Black women facing breast cancer [...]

MD Anderson and Siemens Healthineers collaborating to enable consistent clinical implementation of quantitative MRI

2021-09-30T11:47:11-05:00September 30th, 2021|

The University of Texas MD Anderson Cancer Center and Siemens Healthineers today announced the collaborative development of a global education program focused on enabling the implementation of consistent, high-quality magnetic resonance (MR) imaging in radiation oncology. The program will provide courses for both clinical and administrative groups with the aim of facilitating safe adoption [...]

OncoDNA teams up with SOPHiA GENETICS to enable laboratories to establish data-driven medicine as a standard of care

2021-09-30T11:43:59-05:00September 30th, 2021|

OncoDNA, a genomic and theranostic company specializing in precision medicine for the treatment of patients with cancer and genetic diseases, and SOPHiA GENETICS S.A., a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research, announced today an agreement facilitating the analysis and [...]

GenXys Partners with Helix on an Integrated, Population Health Focused Pharmacogenomic Solution

2021-09-30T11:38:59-05:00September 30th, 2021|

GenXys Health Care Systems (GenXys), the award-winning precision prescribing company, today announced a partnership with Helix, a leading population genomics company working at the intersection of clinical care, research, and genomics. Together, the companies will be working to ensure that "trial-and-error" prescribing becomes a thing of the past, by enabling providers to incorporate actionable [...]

Lantern Pharma Enters into Strategic Collaboration with Deep Lens

2021-09-30T11:36:37-05:00September 30th, 2021|

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development and Deep Lens, a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of [...]

Thermo Fisher Scientific Opens Call for Grant Proposals to Fund Clinical Research in Hematology-oncology

2021-09-30T11:33:09-05:00September 30th, 2021|

To support clinical research needs using next-generation sequencing (NGS), Thermo Fisher Scientific today announced it is accepting new submissions for its Oncomine Clinical Research Grant. The latest call for proposals aims to provide funding for clinical research programs that leverage NGS in solid tumors and hematology-oncology applications. The Oncomine Clinical Research Grant awards independent [...]

Lifebit raises $60m to make vital biomedical data securely accessible for life changing research worldwide

2021-09-30T11:29:38-05:00September 30th, 2021|

Lifebit Biotech Ltd – the leading precision medicine software company democratising access to biomedical data of governments, biobanks and healthcare providers for research teams worldwide – has raised a $60 million Series B funding round, led by global investment firm Tiger Global Management. Existing investors Eurazeo, Pentech Ventures, and Beacon Capital also participated. Despite [...]

Personal Genome Diagnostics and Cleveland Clinic Collaborate to Expand Utility of Liquid Biopsy Applications in Oncology Clinical Research

2021-09-30T11:24:00-05:00September 30th, 2021|

– Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a collaboration with the Center for Immunotherapy and Precision Immuno-Oncology (CITI) and the Cleveland Clinic Lerner Research Institute, Cleveland, Ohio. Both parties will collaborate to enhance capabilities within elioTM plasma complete reporting, as well as collaborate on the development of proprietary [...]

Go to Top